NDA 011963 · Fera Pharms LLC
Phospholine Iodide
Echothiophate Iodide · Ophthalmic
NovelLast checked: Nov 19, 2026Latest source record: Oct 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1960
Jun 27, 1960
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
147
75 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2025.
INDICATIONS AND USAGE Reduction of Elevated IOP Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. Accommodative Esotropia Concomitant esotropias with a significant accommodative component.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 1960 Original approval · Type 1 - New Molecular Entity
4 products under this application
- PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.06% · FOR SOLUTION, OPHTHALMIC · Discontinued
- PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.03% · FOR SOLUTION, OPHTHALMIC · Discontinued
- PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.25% · FOR SOLUTION, OPHTHALMIC · Discontinued
- PHOSPHOLINE IODIDE · ECHOTHIOPHATE IODIDE 0.125% · FOR SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Echothiophate Iodide" as an intervention, any sponsor and status, largest first.
University of OklahomaAcademic, hospital or other
NCT07554131 · 20 participants (planned) · Start Jun 2026 · Primary completion Dec 2026
Drug: Echothiophate Iodide 0.125% Ophthalmic Solution · For: Refractory Amblyopia
Sites: Oklahoma City, Oklahoma
Danbury Eye Physicians & Surgeons, PCAcademic, hospital or other
NCT02544529 · 0 participants · Start Jun 1, 2016 · Primary completion Jun 1, 2016
Drug: Echothiophate Iodide 0.03% Ophthalmic Solution; Carboxymethylcellulose Sodium (0.5%) · For: Myopia
Sites: Danbury, Connecticut
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- intraocular pressure increased27
- drug ineffective22
- visual impairment17
- eye pain13
- visual acuity reduced10
- blindness9
- blindness unilateral8
- ocular hyperaemia8
- eye disorder7
- eye irritation7
- vision blurred7
- glaucoma6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 9 |
| 2012 | 9 |
| 2013 | 11 |
| 2014 | 20 |
| 2015 | 9 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 25 |
| 2021 | 10 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 2, 2026
Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05). Available through limited distribution by Walgreens Specialty Pharmacy.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Phospholine Iodide (Echothiophate Iodide)
2024 spending
$1.1M
Beneficiaries
59
437 claims
Per beneficiary
$19,153
$514.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $341,512 |
| 2023 | $941,693 |
| 2024 | $1,130,040 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Postoperative miotics for patients with infantile esotropia.
Spierer A, Zeeli T · Ophthalmic Surg Lasers 1997 · Clinical Trial, Randomized Controlled Trial
- Dose responses of human intra-ocular pressure to various concentrations of echothiophate iodide.
Stockdill P, Drance SM · Trans Ophthalmol Soc U K (1962) 1965 · Clinical Trial, Controlled Clinical Trial
- Dipivefrin and echothiophate. Efficacy of combined use in human beings.
Mindel JS, Yablonski ME, Tavitian HO, et al. · Arch Ophthalmol 1981 · Clinical Trial, Comparative Study
- Echothiophate iodide. The effect of 0.0625 per cent solution on blood cholinesterase.
Wahl JW, Tyner GS · Am J Ophthalmol 1965 · Clinical Trial
- Effect of echothiophate iodide on the lens.
Morton WR, Drance SM, Fairclough M · Am J Ophthalmol 1969 · Clinical Trial, Randomized Controlled Trial
Sponsor: Fera Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.